{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:06:34Z","timestamp":1785240394538,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:54:00Z","timestamp":1777046040000},"page":"e893-e899.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Celant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pierluigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-9034","authenticated-orcid":false,"given":"Pier Paolo","family":"Olimpieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clml.2026.04.015_bib0001","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2026.04.015_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clml.2026.04.015_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.04.015_bib0004","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.clml.2026.04.015_bib0005","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.015_bib0006","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2026.04.015_bib0007","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1002\/cam4.3071","article-title":"How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian medicines agency (AIFA)","volume":"9","author":"Breccia","year":"2020","journal-title":"Cancer Med"},{"issue":"20","key":"10.1016\/j.clml.2026.04.015_bib0008","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","article-title":"Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study","volume":"8","author":"Matsumura","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.015_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00277-021-04406-1","article-title":"Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second-generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)","volume":"100","author":"Breccia","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.04.015_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/jcss.1997.1504","article-title":"A decision-theoretic generalization of online learning and an application to boosting","volume":"5","author":"Freund","year":"1997","journal-title":"J Comput Syst Sci"},{"key":"10.1016\/j.clml.2026.04.015_bib0011","series-title":"Complex Surveys: A Guide to Analysis Using R","author":"Lumley","year":"2010"},{"key":"10.1016\/j.clml.2026.04.015_bib0012","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan\u2013Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med"},{"issue":"24","key":"10.1016\/j.clml.2026.04.015_bib0013","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.04.015_bib0014","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.clml.2026.04.015_bib0015","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.04.015_bib0016","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:57:14Z","timestamp":1785239834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001151"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}